Minerva Neurosciences Investor Relations Material
Latest events
Q1 2023
Minerva Neurosciences
Q1 2025
12 May, 2025
Q4 2024
24 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Minerva Neurosciences Inc
Access all reports
Minerva Neurosciences Inc is a biopharmaceutical company focused on the development of therapies for central nervous system disorders. The company's research targets conditions such as schizophrenia, depression, and insomnia through proprietary drug candidates. Minerva Neurosciences collaborates with academic and industry partners to advance its clinical programs. The company is headquartered in Burlington, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
NERV
Country
🇺🇸 United States